Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe immune Cells' role in skin scarring disease

NCT ID NCT03559465

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how B cells, a type of immune cell, may contribute to scarring in people with systemic sclerosis (scleroderma). Researchers compared skin and blood samples from 71 participants, including patients and healthy volunteers. The goal was to understand the disease better, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

71 people

The number who actually took part.

Started

Oct 2018

Finished

Feb 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: patients * systemic sclerosis according to ACR-EULAR 2013 * written consent * available insurance Healthy "blood" and healthy "biopsy" controls * written consent * available insurance Exclusion Criteria: patients * overlap with other connective tissue diseases * immunosuppressants in the past 12 months * corticosteroids ≥10mg/d * pregnancy or breast feeding Healthy "blood" and healthy "biopsy" controls * systemic sclerosis according to ACR-EULAR 2013 * another connective tissue diseases * immunosuppressants in the past 12 months * corticosteroids ≥10mg/d * pregnancy or breast feeding * With dysimmune inflammatory diseases (except thyroiditis) * Presenting an infection in progress or within the previous 15 days

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Scleroderma, systemic are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Scleroderma, systemic

Contacts and locations

Locations

  • Hôpital Claude Huriez, CHU

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.